Objective:
To describe the molecular profile of adult granulosa cell tumors (AGCT) of the ovary in order to improve prognostication and elucidate molecular therapeutic targets
- AGCT represent less than 5% of all ovarian tumors
- Nearly 1/3 of patients with AGCT develop recurrent disease, and targeted therapies are limited
- Existing data suggest that FOXL2 mutations are common in AGCT and may be pivotal in the development of AGCT
- Further molecular profiling of AGCT may improve prognostication and identify novel therapeutic targets